PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity May 06, 2022

Show notes

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting May 05, 2022

Show notes

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC May 05, 2022

Show notes

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum May 04, 2022

Show notes

Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.

Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer May 04, 2022

Show notes

Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.

Kristina M. Deligiannidis, MD - Applying Evidence to Practice in Postpartum Depression: Expert Guidance on Integrating Therapeutic Innovations and Shared Decision-Making Strategies to Optimize Patient Care Apr 29, 2022

Show notes

Go online to PeerView.com/HYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in women’s behavioral health shares a downloadable tool kit created for OB/GYNs and other clinicians to facilitate the screening, diagnosis, and treatment of postpartum depression (PPD) and to provide guidance on the use of shared decision-making strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Utilize validated screening tools and current clinical guidelines to facilitate the early diagnosis of PPD, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for PPD, Develop individualized treatment protocols for patients with PPD that incorporate evidence-based care and shared decision-making.

Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency Apr 29, 2022

Show notes

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Anita H. Clayton, MD - Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm Apr 29, 2022

Show notes

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies Apr 29, 2022

Show notes

Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Herbert L. Bonkovsky, MD - Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It? Apr 22, 2022

Show notes

Go online to PeerView.com/DQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in acute hepatic porphyria (AHP) reviews the diagnostic criteria for AHP and examines current treatment options. Upon completion of this activity, participants should be better able to: Apply laboratory and diagnostic assessments to confirm suspicion of AHP, Recognize disease burdens that patients with AHP frequently experience (eg, impact on overall health, quality of life, daily activities), Employ evidence-based treatment regimens that include siRNA therapy, as appropriate, to improve outcomes, minimize disease impact, and reduce the burdens of disease in patients with AHP.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected